Lmcg Investments, LLC Neurocrine Biosciences Inc Transaction History

Lmcg Investments, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$130.86 - $143.19 $4,056 - $4,438	-31 Reduced 0.46%	6,771 $932,000
Q1 2024 May 03, 2024	SELL	$130.4 - $143.74 $342,300 - $377,317	-2,625 Reduced 27.85%	6,802 $938,000
Q3 2023 Nov 02, 2023	BUY	$94.02 - $117.1 $18,145 - $22,600	193 Added 2.09%	9,427 $1.06 Million
Q1 2023 May 04, 2023	BUY	$94.11 - $123.02 $18,633 - $24,357	198 Added 2.19%	9,234 $934,000
Q4 2022 Feb 06, 2023	BUY	$106.72 - $127.06 $1,814 - $2,160	17 Added 0.19%	9,036 $1.08 Million
Q3 2022 Nov 07, 2022	BUY	$92.03 - $107.81 $1,012 - $1,185	11 Added 0.12%	9,019 $958,000
Q1 2022 May 10, 2022	BUY	$72.45 - $94.81 $652,629 - $854,048	9,008 New	9,008 $845,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Lmcg Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Lmcg Investments, LLC with notifications on news.